This trial is evaluating the safety and tolerability of a new drug called MBX 2109 given as a shot under the skin. The study will also look at how well the drug is absorbed and how it affects the body.
1 Primary · 2 Secondary · Reporting Duration: Baseline through Day 40 (part A) or Day 60 (Part B)
80 Total Participants · 3 Treatment Groups
Primary Treatment: MBX 2109 (Part A) · Has Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 21 - 60 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Labcorp Drug Development: Clinical Research Unit||100.0%|